Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014;39(1):20-6.
doi: 10.1159/000357409. Epub 2013 Dec 31.

BK virus replication in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis

Affiliations

BK virus replication in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis

D Geetha et al. Am J Nephrol. 2014.

Erratum in

  • Am J Nephrol. 2014;40(1):96

Abstract

Background: BK virus (BKV) is an important cause of renal dysfunction in kidney transplant (KTX) recipients. Immunosuppression intensity is a major risk factor for BKV replication in these patients. The prevalence of BKV replication in immunosuppressed patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) without transplant is not known.

Methods: Consecutive patients (n = 37) with a diagnosis of GPA (n = 25) or MPA (n = 12) without history of KTX were evaluated for plasma BKV replication by quantitative PCR (group A). Descriptive data were collected. BKV replication in this nontransplant immunosuppressed vasculitis cohort was compared with a historical cohort of vasculitis KTX recipients (group B).

Results: Group A patients had mean disease duration of 75 months. Mean age was 57 years and 54% were female. Mean time from vasculitis onset to BKV testing was 36 months, and 19/37 patients were tested within 24 months of induction therapy. At the time of BKV testing, 73% were on prednisone (P) with azathioprine, mycophenolate mofetil (MMF), methotrexate or leflunomide. None of the nontransplanted vasculitis patients had detectable plasma BKV. Among 35 patients in group B, 16 were tested for BKV; 5/16 (31%) had detectable virus in plasma at a mean of 6 months after TX (p = 0.002). Most (94%) were on maintenance therapy with MMF, P and tacrolimus.

Conclusion: Immunosuppressed patients with GPA/MPA without KTX had no evidence of plasma BKV. However, BKV was common in GPA/MPA patients after KTX, suggesting that replication may be related to differences in immunosuppression, alloimmune activation or differences in host defense mechanisms.

PubMed Disclaimer

Conflict of interest statement

The author’s declare conflict of interest

Duvuru Geetha, MD: Department of Medicine, Division of Nephrology, Johns Hopkins University, Baltimore, Maryland: Has served as consultant and received honoraria from Genentech for educational purposes

The author’s declare no conflict of interest

Stuart M Levine, MD: Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland

Rebecca L Manno, MD: Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland

Alex A Valsamakis, MD: Department of Pathology, Johns Hopkins University, Baltimore, Maryland

Sharon Ghazarian, PhD: Department of Pediatrics, Johns Hopkins University, Baltimore, Maryland

Philip Seo, MD: Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland

Similar articles

Cited by

References

    1. Guillevin L, Durand-Gasselin B, Cevallos R, Gayraud M, Lhote F, Callard P, Amouroux J, Casassus P, Jarrousse B. Microscopic polyangiitis: Clinical and laboratory findings in eightyfive patients. Arthritis and rheumatism. 1999;42:421–430. - PubMed
    1. Finkielman JD, Lee AS, Hummel AM, Viss MA, Jacob GL, Homburger HA, Peikert T, Hoffman GS, Merkel PA, Spiera R, St Clair EW, Davis JC, Jr, McCune WJ, Tibbs AK, Ytterberg SR, Stone JH, Specks U. Anca are detectable in nearly all patients with active severe wegener’s granulomatosis. Am J Med. 2007;120:643. e649-614. - PubMed
    1. Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC, Nachman PH. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med. 2005;143:621–631. - PubMed
    1. Weidner S, Geuss S, Hafezi-Rachti S, Wonka A, Rupprecht HD. Anca-associated vasculitis with renal involvement: An outcome analysis. Nephrol Dial Transplant. 2004;19:1403–1411. - PubMed
    1. Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, Hoglund P, Jayne D, Luqmani R, Mahr A, Mukhtyar C, Pusey C, Rasmussen N, Stegeman C, Walsh M, Westman K. Long-term patient survival in anca-associated vasculitis. Ann Rheum Dis. 70:488–494. - PubMed

Publication types

Substances